Top Page
Medexus Pharmaceuticals Inc
(TSX:MDP)
Medexus Pharmaceuticals Inc (MDP) vs. S&P 500 (SPY)
Medexus Pharmaceuticals Inc Business Overview & Revenue Model
Medexus Pharmaceuticals Inc Financial Statement Overview
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 109.54M | 113.05M | 108.10M | 76.70M | 79.66M | 52.43M | Gross Profit |
| 57.46M | 59.51M | 60.04M | 37.93M | 42.01M | 29.44M | EBIT |
| 10.22M | 10.79M | 7.61M | -15.00M | -1.38M | ― | EBITDA |
| 18.48M | 19.28M | 14.65M | 15.16M | -23.61M | 7.04M | Net Income Common Stockholders |
| 3.56M | -214.00K | 1.22M | -2.88M | -28.26M | ― |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 8.44M | 5.25M | 13.07M | 10.02M | 18.70M | 5.23M | Total Assets |
| 145.98M | 155.73M | 161.33M | 139.22M | 148.51M | 122.81M | Total Debt |
| 39.91M | 49.90M | 70.08M | 54.86M | 44.87M | 38.81M | Net Debt |
| 31.47M | 44.64M | 57.01M | 44.84M | 26.17M | 33.58M | Total Liabilities |
| 112.88M | 125.41M | 138.88M | 121.43M | 130.50M | 98.53M | Stockholders Equity |
| 33.10M | 30.32M | 22.45M | 17.79M | 18.02M | 24.28M |
| Cash Flow | Free Cash Flow | ||||
| 20.47M | 18.45M | -1.81M | -8.89M | -5.72M | ― | Operating Cash Flow |
| 23.36M | 18.71M | -1.44M | -1.18M | 5.04M | ― | Investing Cash Flow |
| -4.48M | -3.48M | -1.72M | -8.20M | -11.70M | ― | Financing Cash Flow |
| -18.33M | -23.05M | 6.41M | 663.00K | 18.68M | 14.60M |
Medexus Pharmaceuticals Inc Technical Analysis
Medexus Pharmaceuticals Inc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | C$601.09M | 137.27 | 0.53% | ― | 13.13% | ― | |
69 Neutral | C$83.55M | 13.00 | 11.27% | ― | -3.82% | -50.36% | |
52 Neutral | C$137.03M | ― | -23.20% | ― | -8.80% | 26.77% | |
51 Neutral | $101.62M | ― | ― | 6.07% | 80.33% | ||
49 Neutral | $6.88B | 0.82 | -52.97% | 2.48% | 20.92% | 1.17% | |
48 Neutral | C$3.89M | ― | -160.58% | ― | 44.96% | -827.30% |
Medexus Pharmaceuticals Inc Earnings Call Summary
Medexus Pharmaceuticals Inc Corporate Events
Medexus Pharmaceuticals has finalized an agreement with NX Development Corp. to return the U.S. commercialization rights for Gleolan, a move that will see NXDC assume responsibility for the product by March 31, 2025. This strategic decision allows Medexus to receive a per-unit payment on Gleolan sales through June 2025, aligning with the company’s interests and ensuring continued availability of the product for patients, while potentially reducing royalty obligations.
Medexus Pharmaceuticals Inc has announced the commercial availability of GRAFAPEX (treosulfan) for Injection in the United States, marking a significant milestone for the company. This product, used as a preparative regimen for allogeneic hematopoietic stem cell transplantation, is expected to greatly enhance Medexus’s market position in the hemato-oncology space. The company anticipates that the annual revenue from GRAFAPEX in the U.S. could exceed $100 million within five years, reinforcing its strategic importance. This development comes shortly after receiving FDA approval and has already generated positive feedback from key institutions, indicating a strong potential impact on Medexus’s operations and revenue growth.
Medexus Pharmaceuticals reported strong fiscal Q3 2025 results with a revenue of $30.0 million, a net income of $0.7 million, and an operating income of $3.8 million. The company attributed the revenue growth to increased sales of Rupall and favorable customer buying patterns for IXINITY, while also noting reduced sales of Rasuvo and Metoject. The company’s financial discipline and strategic investments in personnel and infrastructure for GRAFAPEX™ have contributed to these results, positioning Medexus well for the upcoming U.S. launch of GRAFAPEX.
Medexus Pharmaceuticals has successfully completed agreements with Ontario’s Ministry of Health and Ontario Health for public reimbursement of Trecondyv in Ontario, Canada. This milestone follows the completion of pCPA negotiations and signifies progress in making Trecondyv accessible across Canada. The company is working with other government organizations to further expand public reimbursement, enhancing its market presence and providing critical treatment options for patients with acute myeloid leukemia and myelodysplastic syndromes.
Medexus Pharmaceuticals has scheduled a conference call on February 6, 2025, to discuss its third fiscal quarter results, which ended on December 31, 2024. The announcement indicates the company’s commitment to transparency and communication with stakeholders, providing insights into its financial performance and potential implications for its market positioning.
Medexus Pharmaceuticals Inc. announced the pricing of a $30 million overnight marketed public offering of common shares. The offering, arranged by a syndicate of underwriters led by Raymond James Ltd., aims to raise capital to repay debts and fund general corporate purposes, including business development activities. The closing of the offering is expected around January 31, 2025, subject to customary conditions and Toronto Stock Exchange approval.
Medexus Pharmaceuticals Inc. announces an overnight marketed public offering of common shares, led by Raymond James Ltd. The proceeds will be used to repay a credit from medac, pay a milestone amount, and support working capital and corporate purposes. The offering is conducted via a prospectus supplement and may include private placement in the U.S., subject to regulatory approvals. This move is expected to enhance Medexus’s financial flexibility and support its business development initiatives.
Medexus Pharmaceuticals announced the FDA approval of GRAFAPEX (treosulfan) for injection, a significant development in hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome. The approval is expected to strengthen Medexus’s market position in the U.S., with projections of annual revenue exceeding $100 million within five years post-launch, and it will provide a new treatment option that could improve patient outcomes.
Medexus Pharmaceuticals has successfully completed an agreement with British Columbia’s Provincial Health Services Authority for the public reimbursement of Trecondyv in British Columbia. This milestone marks the first step in Medexus’s efforts to secure public reimbursement for Trecondyv across Canada, enhancing its market potential and accessibility for patients who require this treatment.